About Annexin A9
Annexin A9 (ANXA9) is a protein
from Homo sapiens identified by UniProt accession
O76027, 345 residues long.
MolForge cross-references it against 0 known binders and
116 disease associations.
Target properties
| Protein name | Annexin A9 |
|---|
| UniProt accession | O76027 |
|---|
| Gene | ANXA9 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 345 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (116)
Diseases linked to this target (Open Targets).
- sex hormone-binding globulin measurement · score 0.34
- low density lipoprotein cholesterol measurement · score 0.31
- serum alanine aminotransferase measurement · score 0.30
- serum gamma-glutamyl transferase measurement · score 0.28
- creatinine measurement · score 0.28
- mean corpuscular volume · score 0.27
- glomerular filtration rate · score 0.26
- cystatin C measurement · score 0.24
- aspartate aminotransferase measurement · score 0.23
- apolipoprotein B measurement · score 0.23
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-O76027-F1 | alphafold | PREDICTED | 89.94 | — |
Amino-acid sequence (345 residues)
MSVTGGKMAP SLTQEILSHL GLASKTAAWG TLGTLRTFLN FSVDKDAQRL LRAITGQGVD RSAIVDVLTN RSREQRQLIS RNFQERTQQD LMKSLQAALS GNLERIVMAL LQPTAQFDAQ ELRTALKASD SAVDVAIEIL ATRTPPQLQE CLAVYKHNFQ VEAVDDITSE TSGILQDLLL ALAKGGRDSY SGIIDYNLAE QDVQALQRAE GPSREETWVP VFTQRNPEHL IRVFDQYQRS TGQELEEAVQ NRFHGDAQVA LLGLASVIKN TPLYFADKLH QALQETEPNY QVLIRILISR CETDLLSIRA EFRKKFGKSL YSSLQDAVKG DCQSALLALC RAEDM
Explore Annexin A9 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets